Cornell researchers discover bacteria's metabolic vulnerability to sugar-phosphate buildup

Bacteria are winning the arms race against antibiotics. Strains of E. coli and Staphylococcus aureus have developed defenses against the drugs that once reliably killed them, and the medical establishment is searching urgently for new ways to stop bacterial growth before resistance becomes universal. A team at Cornell's Weill Institute for Cell and Molecular Biology may have found an unexpected vulnerability—not in the bacteria's armor, but in its own metabolism.

The researchers, led by postdoctoral fellow Megan Keller in the laboratory of Tobias Dörr, discovered that when certain sugar-phosphate molecules accumulate inside bacterial cells, they trigger a cascade of failure. These molecules jam up the enzymes responsible for building peptidoglycan, the rigid mesh structure that forms the bacterial cell wall. Without that wall intact, bacteria become fragile and eventually burst. The work, published in mBio in July 2025, used Vibrio cholerae—the bacterium that causes cholera and is known for its ability to resist antibiotics—as the test case. When the team engineered strains to accumulate specific sugar-phosphates, the cells showed dramatic growth defects. Chemical analysis confirmed the mechanism: the sugar-phosphates were directly interfering with the molecular machinery that constructs the cell wall.

What makes this finding potentially powerful is that it works through a completely different pathway than existing antibiotics that also target cell wall synthesis. Most current drugs attack the enzymes directly. This mechanism instead floods the cell with toxic byproducts of its own metabolism. Because the pathway is novel, bacteria may find it harder to evolve resistance to it—at least initially. Keller described the strategy plainly: shut down the bacterium's ability to process sugar while simultaneously making it vulnerable to cell-wall-targeting antibiotics. The combination could trap bacteria between two threats at once.

The research team, which included collaborators from Weill Cornell Medicine with expertise in metabolomics, genetics, and biochemistry, is now exploring how to weaponize this vulnerability. Rather than designing drugs that directly inhibit bacterial enzymes, scientists could instead create compounds that cause sugar-phosphate molecules to pile up to lethal levels inside the cell. The approach is theoretically elegant: peptidoglycan is essential for virtually all bacteria but does not exist in human cells, so therapies based on this mechanism could kill bacteria without harming patients. There is a caveat—the same mechanism would likely kill beneficial microbes in the human microbiome, a trade-off that would need careful consideration.

Dörr framed the discovery as revealing bacteria's internal fragility. "Bacteria carry the seeds of their own destruction," he said. The next phase of work will test whether the same metabolic vulnerability exists in other disease-causing bacteria and screen for molecules that enhance sugar-phosphate accumulation. The long-term goal is to move from basic science into clinical therapies that can outpace the speed at which bacteria develop resistance. If the mechanism proves robust across multiple bacterial species, it could represent a fundamentally new approach to antibiotic development—one that exploits not bacterial strength but bacterial dependency on a process that, when disrupted, becomes lethal.